Nippon Life Insurance Co. Purchases 1,021 Shares of Gilead Sciences, Inc. (GILD)

Nippon Life Insurance Co. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 82,129 shares of the biopharmaceutical company’s stock after buying an additional 1,021 shares during the quarter. Nippon Life Insurance Co.’s holdings in Gilead Sciences were worth $6,654,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sanders Capital LLC bought a new stake in Gilead Sciences during the third quarter worth approximately $427,585,000. Renaissance Technologies LLC boosted its position in Gilead Sciences by 35.0% during the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after purchasing an additional 2,700,600 shares during the period. Vanguard Group Inc. boosted its position in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. The Manufacturers Life Insurance Company boosted its position in Gilead Sciences by 50.0% during the second quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock worth $438,244,000 after purchasing an additional 2,062,886 shares during the period. Finally, BlackRock Inc. boosted its position in Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. 75.94% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.71 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The stock has a market capitalization of $95,360.00, a price-to-earnings ratio of 8.27, a price-to-earnings-growth ratio of -1.24 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.75 earnings per share. equities analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.66%.

GILD has been the subject of a number of recent analyst reports. BMO Capital Markets reaffirmed a “hold” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target for the company in a report on Wednesday, September 6th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $85.03.

In other news, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.56, for a total value of $6,054,372.48. The disclosure for this sale can be found here. Insiders have sold 494,999 shares of company stock worth $37,404,139 in the last 90 days. Company insiders own 1.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Nippon Life Insurance Co. Purchases 1,021 Shares of Gilead Sciences, Inc. (GILD)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/23/nippon-life-insurance-co-purchases-1021-shares-of-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit